American International Group Inc. grew its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 1.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 73,041 shares of the medical research company’s stock after acquiring an additional 1,068 shares during the period. American International Group Inc.’s holdings in Iqvia were worth $11,286,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Usca Ria LLC bought a new position in shares of Iqvia during the third quarter valued at $29,000. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Iqvia by 379.5% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 167 shares during the last quarter. Evolution Wealth Advisors LLC raised its stake in shares of Iqvia by 303.6% during the fourth quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Iqvia during the third quarter valued at $38,000. Finally, Massey Quick Simon & CO. LLC bought a new position in Iqvia during the third quarter worth $43,000. 89.93% of the stock is owned by hedge funds and other institutional investors.
IQV has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Iqvia from a “sell” rating to a “hold” rating and set a $170.00 target price for the company in a research note on Tuesday, February 4th. Credit Suisse Group reissued a “buy” rating and set a $170.00 target price on shares of Iqvia in a research note on Friday, December 20th. JPMorgan Chase & Co. lifted their target price on shares of Iqvia from $180.00 to $195.00 and gave the stock an “overweight” rating in a research note on Thursday. Stifel Nicolaus lifted their target price on shares of Iqvia from to and gave the stock a “buy” rating in a research note on Wednesday. Finally, Robert W. Baird lifted their target price on shares of Iqvia from $172.00 to $181.00 and gave the stock an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $174.30.
In other news, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the completion of the transaction, the chief financial officer now directly owns 14,366 shares in the company, valued at $2,227,735.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael J. Evanisko sold 6,250 shares of Iqvia stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,000 shares of company stock valued at $5,830,215. Insiders own 6.00% of the company’s stock.
IQV opened at $165.79 on Friday. Iqvia Holdings Inc has a 1-year low of $130.77 and a 1-year high of $169.14. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85. The company has a market cap of $31.03 billion, a P/E ratio of 135.89, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. The company has a fifty day moving average price of $157.99 and a two-hundred day moving average price of $151.69.
Iqvia (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.02. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the previous year, the firm posted $1.50 earnings per share. The business’s revenue was up 7.7% compared to the same quarter last year. On average, research analysts forecast that Iqvia Holdings Inc will post 5.9 EPS for the current fiscal year.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: Which market index is the best?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.